Codexis finally finds CFO
This article was originally published in Scrip
Codexis, a developer of industrial enzymes used to make sophisticated pharmaceutical intermediates, has finally found a replacement CFO for Robert Lawson who left the company in January. David O'Toole takes up the role of vice-president and CFO having most recently served as vice-president and CFO at Response Genetics. He has 12 years' experience in the life science and biotech industries.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.